Chikungunya-vesicular Stomatitis Chimeric Virus Targets and Eliminates Brain Tumors

Overview

Journal Virology

Specialty Microbiology

Date 2018 Jul 29

PMID 30055515

Citations 13

Authors

Xue Zhang

Guochao Mao

Anthony N van den Pol

Affiliations

Soon will be listed here.

Abstract

Vesicular stomatitis virus (VSV) shows potential for targeting and killing cancer cells, but can be dangerous in the brain due to its neurotropic glycoprotein. Here we test a chimeric virus in which the VSV glycoprotein is replaced with the Chikungunya polyprotein E3-E2-6K-E1 (VSVΔG-CHIKV). Control mice with brain tumors survived a mean of 40 days after tumor implant. VSVΔG-CHIKV selectively infected and eliminated the tumor, and extended survival substantially in all tumor-bearing mice to over 100 days. VSVΔG-CHIKV also targeted intracranial primary patient derived melanoma xenografts. Virus injected into one melanoma spread to other melanomas within the same brain with little detectable infection of normal cells. Intravenous VSVΔG-CHIKV infected tumor cells but not normal tissue. In immunocompetent mice, VSVΔG-CHIKV selectively infected mouse melanoma cells within the brain. These data suggest VSVΔG-CHIKV can target and destroy brain tumors in multiple animal models without the neurotropism associated with the wild type VSV glycoprotein.

Citing Articles

An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.

Stergiopoulos G, Concilio S, Galanis E Curr Treat Options Oncol. 2024; 25(7):952-991.

PMID: 38896326 PMC: 11878440. DOI: 10.1007/s11864-024-01211-6.

A viral attack on brain tumors: the potential of oncolytic virus therapy.

Mokhtarpour K, Akbarzadehmoallemkolaei M, Rezaei N J Neurovirol. 2024; 30(3):229-250.

PMID: 38806994 DOI: 10.1007/s13365-024-01209-8.

RVG Peptide-Functionalized Favipiravir Nanoparticle Delivery System Facilitates Antiviral Therapy of Neurotropic Virus Infection in a Mouse Model.

Ren M, Zhou Y, Tu T, Jiang D, Pang M, Li Y Int J Mol Sci. 2023; 24(6).

PMID: 36982925 PMC: 10058582. DOI: 10.3390/ijms24065851.

Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.

Hamad A, Yusubalieva G, Baklaushev V, Chumakov P, Lipatova A Viruses. 2023; 15(2).

PMID: 36851761 PMC: 9958853. DOI: 10.3390/v15020547.

Application of mRNA Technology in Cancer Therapeutics.

Eralp Y Vaccines (Basel). 2022; 10(8).

PMID: 36016150 PMC: 9415393. DOI: 10.3390/vaccines10081262.

References

van den Pol A, Spencer D . Differential neurite growth on astrocyte substrates: interspecies facilitation in green fluorescent protein-transfected rat and human neurons. Neuroscience. 2000; 95(2):603-16. DOI: 10.1016/s0306-4522(99)00430-3. View

Stojdl D, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N . Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000; 6(7):821-5. DOI: 10.1038/77558. View

Rose N, Marx P, Luckay A, Nixon D, Moretto W, Donahoe S . An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001; 106(5):539-49. DOI: 10.1016/s0092-8674(01)00482-2. View

van den Pol A, Dalton K, Rose J . Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol. 2002; 76(3):1309-27. PMC: 135838. DOI: 10.1128/jvi.76.3.1309-1327.2002. View

Obuchi M, Fernandez M, Barber G . Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol. 2003; 77(16):8843-56. PMC: 167243. DOI: 10.1128/jvi.77.16.8843-8856.2003. View

van den Pol A, Finkbeiner S, Cornell-Bell A . Calcium excitability and oscillations in suprachiasmatic nucleus neurons and glia in vitro. J Neurosci. 1992; 12(7):2648-64. PMC: 6575860. View

Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004; 78(10):5458-65. PMC: 400370. DOI: 10.1128/jvi.78.10.5458-5465.2004. View

Wollmann G, Tattersall P, van den Pol A . Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol. 2005; 79(10):6005-22. PMC: 1091699. DOI: 10.1128/JVI.79.10.6005-6022.2005. View

Clarke D, Cooper D, Egan M, Hendry R, Parks C, Udem S . Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol. 2006; 28(3):239-53. PMC: 7079905. DOI: 10.1007/s00281-006-0042-3. View

10.

Lun X, Senger D, Alain T, Oprea A, Parato K, Stojdl D . Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst. 2006; 98(21):1546-57. DOI: 10.1093/jnci/djj413. View

11.

Powers A, Logue C . Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol. 2007; 88(Pt 9):2363-2377. DOI: 10.1099/vir.0.82858-0. View

12.

Allen C, Paraskevakou G, Liu C, Iankov I, Msaouel P, Zollman P . Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther. 2008; 8(2):213-20. PMC: 2756986. DOI: 10.1517/14712598.8.2.213. View

13.

Ozduman K, Wollmann G, Piepmeier J, van den Pol A . Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci. 2008; 28(8):1882-93. PMC: 6671450. DOI: 10.1523/JNEUROSCI.4905-07.2008. View

14.

Ziegler S, Lu L, Travassos da Rosa A, Xiao S, Tesh R . An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg. 2008; 79(1):133-9. View

15.

Geisbert T, Daddario-DiCaprio K, Lewis M, Geisbert J, Grolla A, Leung A . Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4(11):e1000225. PMC: 2582959. DOI: 10.1371/journal.ppat.1000225. View

16.

Geisbert T, Geisbert J, Leung A, Daddario-DiCaprio K, Hensley L, Grolla A . Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009; 83(14):7296-304. PMC: 2704787. DOI: 10.1128/JVI.00561-09. View

17.

Chandak N, Kashyap R, Kabra D, Karandikar P, Saha S, Morey S . Neurological complications of Chikungunya virus infection. Neurol India. 2009; 57(2):177-80. DOI: 10.4103/0028-3886.51289. View

18.

Ozduman K, Wollmann G, Ahmadi S, van den Pol A . Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. J Virol. 2009; 83(22):11540-9. PMC: 2772672. DOI: 10.1128/JVI.02558-08. View

19.

Solignat M, Gay B, Higgs S, Briant L, Devaux C . Replication cycle of chikungunya: a re-emerging arbovirus. Virology. 2009; 393(2):183-97. PMC: 2915564. DOI: 10.1016/j.virol.2009.07.024. View

20.

Galivo F, Diaz R, Wongthida P, Thompson J, Kottke T, Barber G . Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther. 2009; 17(2):158-70. PMC: 3934361. DOI: 10.1038/gt.2009.161. View